{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=7", "query": { "intervention": "Investigator's Treatment of Choice", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 245, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T21:13:35.770Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05549297", "title": "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" }, { "name": "Tebentafusp with Pembrolizumab", "type": "DRUG" }, { "name": "Investigators Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2022-12-19", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05549297" }, { "nct_id": "NCT04494425", "title": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "105 Years", "sex": "ALL", "summary": "18 Years to 105 Years" }, "enrollment_count": 866, "start_date": "2020-07-24", "completion_date": "2026-06-19", "has_results": true, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04494425" }, { "nct_id": "NCT05328908", "title": "A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Nivolumab-relatlimab FDC", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 769, "start_date": "2022-04-28", "completion_date": "2025-07-14", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 20, "location_summary": "Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05328908" }, { "nct_id": "NCT05061550", "title": "Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Monalizumab", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" }, { "name": "AZD0171", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed/Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed/Carboplatin", "type": "DRUG" }, { "name": "Carboplatin/Paclitaxel", "type": "DRUG" }, { "name": "Volrustomig", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 630, "start_date": "2022-04-14", "completion_date": "2030-05-28", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061550" }, { "nct_id": "NCT07116174", "title": "A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Foot Ulcer (DFU)" ], "interventions": [ { "name": "Xcell Amnio Matrix", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "New Horizon Medical Solutions", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2025-08-15", "completion_date": "2026-08-15", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 3, "location_summary": "Fresno, California • San Diego, California • Dallas, Texas", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07116174" }, { "nct_id": "NCT00803634", "title": "Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension", "Heart Failure" ], "interventions": [ { "name": "Clevidipine", "type": "DRUG" }, { "name": "Standard of Care IV antihypertensive", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2008-12", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2014-08-29", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 9, "location_summary": "Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Inglewood", "state": "California" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803634" }, { "nct_id": "NCT01084252", "title": "Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancy" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2010-05-11", "completion_date": "2023-07-13", "has_results": true, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01084252" }, { "nct_id": "NCT01655693", "title": "Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Doxorubicin 20 mg/m2", "type": "DRUG" }, { "name": "Doxorubicin 30 mg/m2", "type": "DRUG" }, { "name": "Best Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 397, "start_date": "2012-06", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 3, "location_summary": "Canton, Ohio • Hershey, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01655693" }, { "nct_id": "NCT02213042", "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Aromatase Inhibitors (AIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2014-10-24", "completion_date": "2020-06-04", "has_results": true, "last_update_posted_date": "2021-10-13", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 3, "location_summary": "Mobile, Alabama • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213042" }, { "nct_id": "NCT06356311", "title": "A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Trifluridine-Tipiracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Rescue medications", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-05-03", "completion_date": "2027-05-06", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-13T21:13:35.770Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06356311" } ] }